The relationships between alcohol, wine and cardiovascular diseases – A review

Creina S. Stockley*

The Australian Wine Research Institute, Glen Osmond, South Australia, Australia

Abstract. The relationship between alcohol consumption and the risk of cardiovascular disease has now been studied for over fifty years, and confirmed in multiples case-controlled and cohort studies, and subsequent meta-analyses of these studies. Sound experimental and clinical studies of plausible biological mechanisms support that there is a causal relationship between alcoholic beverages and cardiovascular disease. While beer, wine and spirits all contain alcohol, they are not necessarily equal in their effects on cardiovascular health, such as the incidence and mortality of coronary heart disease, stroke and all-cause mortality. Hence this review evaluates the available evidence, and details the biological mechanisms and attributes a percentage reduction in harm where possible.

Keywords: Alcohol, wine, cardiovascular disease, coronary heart disease, myocardial infarction

1. Introduction

Cardiovascular disease (CVD) in its various clinical manifestations, for example, hypertension, coronary (artery) heart disease, myocardial infarction (MI), congestive heart failure and stroke, still represents a major public health and financial burden worldwide despite knowledge of modifiable risk factors and accessibility to drug and non-drug therapies [1].

CVD involves a complex interplay between multiple altered cellular and molecular functions in heart muscle (such as cardiomyocytes), blood vessels (such as endothelial cells), vascular smooth muscle cells, blood cells (such as platelets and monocytes) and plasma components (such as lipoproteins, and blood clotting and blood flow factors) as well as gene function [2]. Accordingly, there are multiple biological mechanisms involved in reducing the risk of cardiovascular diseases, including haemostatic effects on a blood pressure and blood flow, anti-inflammatory effects and enhanced endothelial function, that is the ability of the artery wall to expand and contract, thus providing a protective effect during the early phases of atherosclerosis [3–6]. Atherosclerosis is the underlying cause of most cardiovascular diseases. The lining of the artery wall (endothelium) plays a crucial role in regulating blood flow and the supply of oxygen to organs and tissues through the production of nitric oxide [7]. Nitric oxide regulates arterial tone, that is, how much the arteries resist being stretched, and exerts significant anti-inflammatory and anti-atherosclerotic effects [7]. Endothelial dysfunction, which is the inability of the lining of the artery wall to expand and contract, has been shown to be an independent predictor of cardiovascular disease even after adjusting for traditional risk factors such as hypertension and hypercholesterolaemia, which are characterised by an impairment of endothelium-dependent vasodilatation [8]. Atherosclerotic lesions are also commonly observed in the peripheral arteries of patients with the inter-related peripheral artery disease.

While CVD is the leading cause of death in developed countries accounting for 25–50% of all deaths, its incidence varies 10-fold across different countries [9, 10]. Sources of the variation across different countries include differences in the risk factors for cardiovascular disease, such as body mass index.
(BMI), diet and exercise, disease status, in particular diabetes mellitus, genetic predisposition, medical intervention and treatment, systolic blood pressure, serum cholesterol concentration, balance between high and low density lipoprotein, cigarette smoking and socioeconomic status as well as differences in the amount, pattern and even type of alcoholic beverage consumed [11, 12].

Between 1980 and 2006, Australia had one of the greatest declines in CVD death rates compared to the other OECD countries. In 2009, however, CVD-related deaths still accounted for 32.8% of the total number of deaths in Australia, and 18% of the overall burden of disease in Australia [13, 14]. Coronary heart disease (CHD) and stroke contributed over 80% of this burden. For example, CHD deaths accounted for 49% of all CVD deaths and 16% of deaths from all causes and stroke deaths accounted for 18% of CVD deaths and 6% of all deaths. From the WHO’s Global Status Report on Alcohol and Health 2014, Australian per capita alcohol consumption has been stable over the last decade at approximately 10.4 L of pure alcohol. Also, its patterns of drinking score is calculated to be two, where one is least risky drinking pattern and five is most risky [15].

Improving haemostatic effects, anti-inflammatory effects and endothelial function associated with CVD by means of non-drug therapies such as the inclusion of the moderate consumption of alcoholic beverages, and in particular wine, in the daily diet might represent an important therapeutic target [8, 16].

This review paper discusses the available published literature on the relationships between CVD and the consumption of alcoholic beverages, and specifically wine, through a systematic search of the electronic database PUBMED from January 1980 up to May 2014. The published literature includes meta-analyses, relevant reviews, experimental and clinical studies, and references of identified papers, but excluded letters, editorials, conference abstracts and commentaries. No language restrictions were applied.

2. Relationship between alcohol consumption and CVD – Early studies

The primary classifications of alcoholic beverages are wine, beer and spirits, the consumption of which depends on the country and its cultures [17]. All alcoholic beverages contain alcohol as their characterising ingredient. Wine, for example, typically contains the following alcohols in measurable amounts: methyl, ethyl, n-propyl, iso-propyl, iso-butyl, iso-amyl, act-amyl, 2-phenethanol, n-hexanol as well as detectable amounts of approximately 18 other alcohols [18]. The most abundant alcohol is ethyl alcohol or ethanol, where the concentration of ethanol in ‘table’ wine generally ranges between 8 and 15% v/v [19].

In 1915, the first description was published of a relationship between the prevalence of hypertension and the amount of alcohol consumed by French Troops on the western front during World War I [20]. A J-shaped relationship between amount of alcohol consumed and risk of cardiovascular diseases such as hypertension was first observed in 1974 by Klatsky et al. and independently by St Leger et al. in 1979 (Fig. 1A) [21, 22].

Thirty-five years later, there is now an accepted inverse relationship between moderate alcohol consumption and CVD that is acknowledged by the World Health Organisation [23, 24]. For example, the WHO’s Global Status Report on Alcohol 2011 and reiterated in the 2014 version, includes the following statement: “The relationship between alcohol consumption and cardiovascular diseases is complex [15, 25]. Light to moderate drinking can have a beneficial impact on morbidity and mortality for ischaemic heart disease and ischaemic stroke. However, the beneficial cardioprotective effect of drinking disappears with heavy drinking occasions.”

Initial observations of the 1970s have been followed by a series of large scale, cross-sectional, longitudinal and prospective epidemiological studies (Fig. 1B). Almost all of these studies have demonstrated a J-shaped relationship between the consumption of alcoholic beverages such as wine, and the risk of, and death from, CVD [26–39]. The risk of CVD is decreased with moderate consumption compared to abstinence but increases again with heavier consumption [40].

3. Relationship between alcohol consumption and CVD – Later studies and meta-analyses

It has been suggested that confounding may have lead to bias in the majority of the studies that were undertaken between 1974 and 2005, and consequently that any cardioprotection afforded by
alcoholic beverages had been overestimated [43–45]. The suggested confounding was misclassification of ex-drinkers who are at higher risk of ischaemic heart disease in the abstainer category, thereby inflating the risk of abstainers compared with moderate drinkers. Ischaemic heart disease is also referred to as coronary heart disease.

3.1. Later studies

Reanalysis of the earlier studies [42, 46] and subsequent studies undertaken that have separated ex-drinkers from lifetime abstainers [47–58], all show that most of these earlier studies still support a J-shaped relationship between alcohol consumption and CVD. Ex-drinkers, lifetime abstainers and heavy consumers all show increased CVD and mortality risks compared to moderate consumers. By consensus, heavy consumption is generally considered to be greater than 30–40 g alcohol/day, while moderate consumption is less than 30–40 g alcohol/day. Cardioprotection has been consistently observed for both men [50] and women [59] in diverse ethnic populations [60–67]. It is also generally observed when controlling for known confounding factors such as body mass index (BMI), cigarette smoking, diet and exercise [50, 57, 68–73]. Indeed, Rimm and Moats (2007) addressed the issue of residual confounding by healthy lifestyle in drinkers in a large prospective
3.2. Meta-analyses

Through a systematic search of the electronic database PUBMED from January 1980 up to May 2014, 20 published papers of meta-analyses on the relationship of alcohol consumption to CVD were identified which is shown in Table 1. Two meta-analyses assessed cardiovascular disease per se, seven coronary heart disease, one myocardial infarction, one heart failure, two atrial fibrillation, two hypertension, three stroke and three all-cause mortality. No meta-analyses specifically assessed peripheral artery disease. Studies from at least 20 different countries were included, and not all meta-analyses included the same studies. None of the meta-analyses differentiated between different types of alcoholic beverages.

From the analysis of eight prospective studies (five cohort and three randomized studies) from 1988 to 2008, encompassing 16,351 subjects, which all showed a J-shaped relationship between alcohol consumption and CVD, Constanzo et al. (2012) calculated that the percentage reduction in risk was 22% (13–30%), where the optimal amount associated with this reduction was between 8 to 26 g alcohol/day [75]. A more conservative calculation of a 0.6 to 1.8% reduction in risk for women and men, respectively, was made by Inoue et al. (2012) on six Japanese cohort studies which was associated with up to 46 g alcohol/day for women and less than 69 g alcohol/day for men [76].

When myocardial infarction was specifically considered, the reduction in risk was calculated to be 18% (11–24%) for 10 g alcohol/day by Maclure (1993) from 42 cohort studies from 1968 to 1993 that encompassed 52,364 subjects [77]. All five meta-analyses consistently calculated a J-shaped relationship between alcohol consumption and CVD [41, 78–80] including that of Fillmore et al. [44]. From six prospective studies undertaken from 2001 to 2007 and encompassing 164,479 subjects, Padilla et al. (2010) calculated that the reduction in risk of heart failure was 23% (5–37%) with less than 140 g alcohol/week, or approximately 10 g alcohol/day [81].

A recent review of 44 cohort and case-control studies undertaken from 1980 to 2010 on alcohol consumption and coronary heart disease calculated a 25% (0.12 to 36%) and 46% (35 to 55%) reduced risk of developing coronary heart disease for men and women, respectively [81]. This was observed at an average intake of 63 g alcohol/day for men but only 14 g/day for women. Alcohol consumption in men, however, was associated with a linear dose response relationship and detrimental effects for other diseases such as cancers, hypertension, liver cirrhosis and pancreatitis as well as injuries and violence [41]. Corrao et al. (2004) only observed a similar maximal reduced coronary heart disease risk at 20 g alcohol/day for men and women, although cardioprotection was observed up to 72 g/day [41]. The corresponding maximal reduced risk of coronary heart disease mortality was calculated as 22% (0.3 to 37%) at 31 g alcohol/day for men and 18% (0.4 to 26%) at 11 g/day for women. The studies all had life-time abstainers as the reference category to avoid the confounding proposed by Fillmore et al. (2006) and to provide strength of the evidence of a cardioprotective and causal association. Indeed the authors concluded that “based on our meta-analysis, some form of cardioprotective association for ischaemic heart disease [coronary heart disease] morbidity and mortality is hard to deny, given epidemiological evidence”. The gender difference in the calculated risk probably reflects the different physiology of men and women. For example, women typically have lower body weight, smaller liver capacity to metabolize alcohol, and a higher proportion of body fat, which together contribute to women achieving higher blood
<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of studies analysed</th>
<th>Total number of subjects</th>
<th>Time point of studies</th>
<th>Reduction in relative risk shown for moderate consumption</th>
<th>% Reduction in relative risk shown for moderate consumption (=95% CI)</th>
<th>Optimal (lowest risk) amount of alcohol</th>
<th>Differentiation between alcoholic beverages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maclure (1993)</td>
<td>42 cohort</td>
<td>52,364</td>
<td>1968–1993</td>
<td>Yes for MI (27/42 studies)</td>
<td>Non-fatal MI = 0.82 (0.76–0.89)</td>
<td>10 g/day</td>
<td>no</td>
</tr>
<tr>
<td>Holman et al. (1996)</td>
<td>16 cohort</td>
<td>1,084,733</td>
<td>1980–1993</td>
<td>Yes for total mortality (13/16 studies)</td>
<td>Men: 0.84 Women: 0.88</td>
<td>Men: 1.0–1.9 drinks/day Women: 0.1–0.9 drinks/day</td>
<td>no</td>
</tr>
<tr>
<td>Corrao et al. (1999)</td>
<td>200 (153 case control and 47 cohort)</td>
<td>97,351</td>
<td>1966–1998</td>
<td>Yes for Ischaemic stroke No for haemorrhagic stroke</td>
<td>Ischaemic stroke = 0.9 (0.3–2.4) Haemorrhagic stroke = 1.5 (1.3–1.6)</td>
<td>25 g/day</td>
<td>no</td>
</tr>
<tr>
<td>Corrao et al. (2000)</td>
<td>51 (23 case control, 28 cohort)</td>
<td>1,817,323</td>
<td>1974–1998</td>
<td>Yes for CHD</td>
<td>0.80 (0.92–1.00)</td>
<td>20 g/day</td>
<td>no</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of studies analysed</th>
<th>Total number of subjects</th>
<th>Time point of studies</th>
<th>Reduction in relative risk shown for moderate consumption</th>
<th>% Reduction in relative risk shown for moderate consumption (=95% CI)</th>
<th>Optimal (lowest risk) amount of alcohol</th>
<th>Differentiation between alcoholic beverages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reynolds et al. (2003) Alcohol consumption and risk of stroke. A meta-analysis. Journal of the American Medical Association. 289(5):579-588.</td>
<td>35 (16 case control, 19 cohort)</td>
<td>4,469/486,590</td>
<td>1983–2002</td>
<td>Yes for total stroke and ischaemic stroke</td>
<td>Total stroke = 0.83 (0.75–0.91)</td>
<td>Total stroke: &lt;12 g/day Ischaemic stroke: 12–24 g/day</td>
<td>no</td>
</tr>
<tr>
<td>Corrao et al. (2004) A meta-analysis of alcohol consumption and the risk of 15 diseases. Preventative Medicine 38:613-619.</td>
<td>28 cohort</td>
<td>49,640/893</td>
<td>1966–1998</td>
<td>Yes for CHD</td>
<td>0.80 (0.79–0.83)</td>
<td>20 g/day</td>
<td>no</td>
</tr>
<tr>
<td>Fillmore et al. (2006) Moderate alcohol use and reduced mortality risk. Addiction Research and Theory 14:101-132.</td>
<td>54</td>
<td></td>
<td>1974–2001</td>
<td>Yes for occasional – light drinking and CHD mortality</td>
<td>0.94 (0.77–1.00)</td>
<td>11 g/day</td>
<td>no</td>
</tr>
<tr>
<td>Taylor et al. (2009) Alcohol and hypertension: gender differences in dose-response relationships determined through</td>
<td>12 cohort</td>
<td></td>
<td>1991–2006</td>
<td>Hypertension = yes for women</td>
<td>0.82 (0.73–0.93)</td>
<td>5 g/day</td>
<td>no</td>
</tr>
<tr>
<td>Study (2010)</td>
<td>Total number</td>
<td>Study population</td>
<td>Duration</td>
<td>Type of study</td>
<td>Alcohol consumption and cardiovascular disease</td>
<td>Blood alcohol levels</td>
<td>Ischemic stroke/heart disease?</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
<td>-----------------</td>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------------------------</td>
<td>--------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Costanzo et al.</td>
<td>16,351 people</td>
<td>8 prospective studies (5 cohort, 3 randomized controls)</td>
<td>1988–2008</td>
<td>Yes for CVD</td>
<td>22% (13–30%)</td>
<td>8 g/day (up to 26 g/day)</td>
<td>no</td>
</tr>
<tr>
<td>Liu et al.</td>
<td>177,723 men</td>
<td>15 prospective cohort</td>
<td>Yes for CHD</td>
<td>0.46 (0.32–0.67)</td>
<td>41–60 g/day</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Padilla et al.</td>
<td>164,479 people</td>
<td>6 prospective cohort</td>
<td>Yes for HF</td>
<td>0.77 (0.63–0.95)</td>
<td>&gt;14 drinks/week</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Roerecke and Rehm</td>
<td>1980–2009</td>
<td>14 (10 cohort, 4 case-control)</td>
<td>No for CHD</td>
<td>1.45 (1.24–1.70)</td>
<td>≥5 drinks/day</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Samokhvalov et al.</td>
<td>67,891 people</td>
<td>8 (7 cohort, 1 case-control)</td>
<td>No for AF</td>
<td>Men: 1.08 (1.04–1.11) re 24 g/day</td>
<td>Threshold = 3 drinks/day (men)</td>
<td>no</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Table 1
(Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of studies analysed</th>
<th>Total number of subjects</th>
<th>Time point of studies</th>
<th>Reduction in relative risk shown for moderate consumption</th>
<th>% Reduction in relative risk shown for moderate consumption (95% CI)</th>
<th>Optimal (lowest risk) amount of alcohol</th>
<th>Differentiation between alcoholic beverages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patra et al. (2010)</td>
<td>26 (9 case-control, 17 cohort)</td>
<td>1986–2009</td>
<td>Yes for ischaemic stroke for both men and women</td>
<td>0.86 (0.81–0.93)</td>
<td>≥12 g/day (men and women)</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Kodama et al. (2011)</td>
<td>14 (9 cohort, 5 case-control)</td>
<td>126,051</td>
<td>1985–2008</td>
<td>No for AF</td>
<td>1.51 (1.31–1.74)</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Ronksley et al. (2011)</td>
<td>84 prospective cohort</td>
<td>1980–2009</td>
<td>Yes for CVD, CHD and ischaemic stroke mortality</td>
<td>CVD mortality = 0.75 (0.70–0.80)</td>
<td>2.5–14.9 g/day</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Total (N)</td>
<td>Year</td>
<td>Findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------</td>
<td>-----------</td>
<td>-------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Briasoulis et al. (2012)</td>
<td>Prospective</td>
<td>227,656</td>
<td>1997–2010</td>
<td>Yes for all-cause mortality 1.06 (0.91–1.23) for men; 0.83 (0.80–0.86) for women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inoue et al. (2012)</td>
<td>Cohort</td>
<td>309,082</td>
<td>1999–2006</td>
<td>Yes for CVD mortality 1.8% (men), 0.6% (women)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roerecke and Rehm (2012)</td>
<td>Observational</td>
<td>957,684</td>
<td>1980–2010</td>
<td>Yes for CHD mortality 0.78 (0.63–0.97) (men), 0.84 (0.74–0.96) (women)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
alcohol concentrations than men for the same amount of alcohol consumed [82]. It also reflects that women are more sensitive or susceptible to organ and tissue damage from alcohol than men.

The most comprehensive and relatively recent review of 84 prospective studies undertaken from 1980 to 2009 also used lifetime abstainers as the reference category [83]. Alcohol consumption of 2.5 to 14.9 g/day was consistently associated with a 14–25% reduced risk of cardiovascular disease mortality, and specifically the incidence of, and mortality from coronary heart disease and stroke per se. This reduced risk was observed for both men and women for coronary heart disease but the reduction was less for women for stroke, consistent with observations of other meta-analyses. The inclusion of former drinkers did not appear to bias the association of alcohol consumption with cardiovascular disease.

As concluded by Ronksley et al. (2011), the overall association between alcohol consumption and cardiovascular disease and coronary heart disease was actually apparent over 10 years ago, and more recent studies and meta-analyses undertaken have not significantly altered the estimated associations [83]. Concerning all-cause mortality, the 1996 Australian meta-analysis by Holman et al. of 16 cohort studies undertaken between 1980 and 1993, was the first to suggest that the J-shaped relationship between alcohol and CVD could be extended to total or all-cause mortality. A 16% and 12% reduction in risk of death from all-causes was calculated for men and women, respectively, at 10–19 and 1–9 g alcohol/day.

Ten years later, a larger meta-analysis by Di Castelnuovo et al. (2006) of 34 studies undertaken between 1980 and 2005 corroborated this initial observation. It suggested that there was now a 17 and 18% reduced risk for men and women, respectively, which could be extended out to approximately 40 g/day for men and 20 g/day for women [49].

From all these studies and meta-analyses (Table 1), it can be estimated that the moderate consumption of an alcoholic beverage such as wine can reduce the relative risk of, and mortality from, cardiovascular diseases by approximately 25–30%, as compared to that of abstention and excessive consumption.

3.3. Effect of age on the relationship between alcohol consumption and CVD

The relationship between alcohol consumption and the risk of all-cause mortality appears to be age dependent [85]. A cardioprotective effect is first observed when risk factors for CVD begin to influence medium and long-term health, that is, at approximately age 40 years for men and approximately age 50 years for women [86, 87]. Accordingly, in women, onset of cardioprotection depends on the age of onset of menopause and use of hormone replacement therapy [36, 42, 49, 84, 88–90].

Furthermore, initiation of moderate alcohol consumption at ages 45–64 years is also associated with an up to 40% reduction in CVD risk compared to both abstinence and light consumption after approximately four years which was maintained even when other CVD risk factors were considered [91–93].

Cardioprotection generally continues past 65 and 75 years of age [94–97]. Simons et al. (2014), for example, in a population of 2,805 non-institutionalised subjects aged 60 years and older, observed that at 20 years of follow-up, there is significant protection from CVD for moderate alcohol consumers compared to both abstainers and heavy consumers [97]. In addition, men and women consuming any alcohol survived 12 months longer than their abstinent peers. This relationship did not appear to be impacted or mediated by the CVD risk factors of diabetes, hypertension, obesity or the ratio of LDL to HDL cholesterol.

There is also data that suggests that the consumption of alcohol at a younger age does reduce the risk of CVD at a later age [98–101] by modulating certain biomarkers for CVD.

3.4. Effect of pre-existing CVD on the relationship between alcohol consumption and CVD

While the earlier studies focused on healthy individuals, the J-shaped relationship between CVD risk and alcohol consumption appears conserved among moderate alcohol consumers with pre-existing CVD conditions such as hypertension [102–106]. In individuals with pre-existing hypertension, moderate alcohol consumption has been observed to be inversely associated with CVD events such as MI [107], heart failure [108] and ischaemic stroke [109]. In the 10,530 patient population of the EPIC-NL cohort followed for 9.4 years, the association was specifically seen with wine consumption and not beer or spirits. Similar inverse associations have been observed for angina pectoris and previous revascularization [110].
In survivors of an acute myocardial infarction, long-term moderate alcohol consumption is inversely associated with all-cause and cardiovascular mortality among men who survived a first MI [111]. This J-shaped relationship may, however, be strongest among individuals with less impaired cardiac function after MI and should be examined further [112, 113].

The J-shaped relationship between CVD risk and alcohol consumption is also conserved among moderate alcohol consumers with pre-existing cerebrovascular disease, that is, individuals who survived a stroke [114].

3.5. Relationship between alcohol and individual cardiovascular diseases

In addition to reducing the risk of atherosclerosis-related cardiovascular events, such as coronary heart disease and myocardial infarcts, studies have also considered the relationship between alcohol and the specific cardiovascular diseases of atrial fibrillation, heart failure, hypertension and peripheral vascular disease as well as to non-coronary CVD diseases such as stroke [35, 47, 54, 69, 108, 115–120]. Light-to-moderate drinking was observed as generally beneficial in minimising the risk of these cardiovascular events, even after accounting for incident MI, except for atrial fibrillation and hypertension [121, 122]. Heart failure, for example, is a complex syndrome with multiple causes including coronary heart disease, endomyocardial fibrosis, hypertension, myocardial infarction, obesity and type 2 diabetes [123, 124]. Accordingly, the relationship between alcohol and the risk of heart failure appears to be a summation of the relationships between alcohol and the risk of the contributing cardiovascular events [47, 81]. From the US Physician’s Health Study I (1982 to 2008), moderate alcohol consumption independently and jointly with five other healthy lifestyle habits, reduced the lifetime risk of heart failure [54].

3.6. Atrial fibrillation

The relationship between atrial fibrillation, a common chronic cardiac arrhythmia, and alcohol appears to be a casual, linear and dose-response relationship, which may reflect alcohol-induced electrophysiological changes in atrial cells [121, 122, 125–127]. Atrial fibrillation is closely associated with both heart failure and hypertension.

3.7. Hypertension

For hypertension, the relationship with alcohol is consistently J-shaped for women, with a maximal cardioprotective effect observed at approximately 5–15 g/day, while the risk of hypertension increases linearly for men with each drink [128–132]. As only women appear to benefit from light to moderate alcohol consumption, this suggests that the mechanisms underlying the benefit may be different to those for coronary heart disease where both men and women equally benefit from moderate alcohol consumption. Alternatively, differences in the pattern of consumption, beverage choices, diet and lifestyle may account for the gender differences.

3.8. Stroke

There are two primary types of stroke, ischaemic and haemorrhagic, and alcohol has a different relationship with the risk of each type. Ischaemic stroke results from the blockage of an intracerebral artery, either through a local blood clot or a distal embolism, which may be a blood clot, a fat globule or a gas bubble in the bloodstream. Its risk factors are atrial fibrillation and hypertension [133]. Consequently, the apparent inverse association of moderate alcohol consumption and risk of ischaemic stroke occurs at a lower amount of alcohol and with a lower magnitude of risk reduction than does the corresponding association with risk of CHD [50, 83, 134–136]. Only a regular pattern of light consumption is consistently associated with a reduced risk of ischaemic stroke [66, 132, 138]. For example, in the Prospective Epidemiological Study of Myocardial Infarction (PRIME), binge drinking approximately doubled the risk of an ischaemic stroke compared with regular consumption [138].

There is consensus among studies that heavy alcohol consumption is always associated with a higher risk of both ischaemic and haemorrhagic strokes. The relationship between moderate alcohol consumption and haemorrhagic stroke is less certain. Some studies have observed a J-shaped relationship while others observed a linear and dose-dependent relationship between the amount of alcohol consumed and the risk of hemorrhagic stroke [41, 139, 140–142]. If J-shaped, the optimal amount of alcohol is even lower than that for ischaemic stroke. For example, while Corrao et al. (2004) calculated a significantly increased risk for ischaemic stroke
at 100 g alcohol/day, for haemorrhagic stroke this was calculated at 50 g/day [41]. This difference in risk between stroke types may be associated with an alcohol-induced increase in blood pressure in heavier consumers [139, 143].

These observations may reflect the alcohol-induced reduction in blood clotting which decreases the risk of a blood clotting-related event such as a myocardial infarction and an ischaemic stroke, but increases the risk of bleeding or a haemorrhage in the brain [144].

3.9. Mechanisms of alcohol in reducing CVD risk

CVD and atherosclerosis result from an interaction of lipids, haemostasis, inflammatory, endothelial factors and hormonal factors. Accordingly, cholesterol or lipid values, for example, are a biomarker and risk indicator for coronary and vascular diseases. Plasminogen activator inhibitor, tissue plasminogen activator, plasminogen, von Willebrand factors, fibrinogen, thromboxane and e-selectin are biomarkers for haemostasis. C-reactive protein, leukocytes and the pro-inflammatory cytokines, interleukin and tumor necrosis factor-α, are biomarkers for inflammation. Intracellular adhesion molecule and vascular cell adhesion molecule are biomarkers for endothelial function as well as inflammation, and adiponectin and leptin are adipocyte hormone biomarkers. These proposed mechanisms of alcohol in reducing CVD are summarised in Table 2.

A meta-analysis of 42 experimental studies, which examined the effects of alcohol consumption on CVD biomarkers, attributed the cardioprotective effect of light-to-moderate alcohol consumption: 60% of this cardioprotection was attributed to effects on high density lipoprotein, 20–30% to fibrinogen, 5–10% to insulin and 0–5% to other haemostatic factors [145]. The meta-analysis also estimated that 30 g of alcohol per day would increase the plasma concentration of high density lipoprotein (HDL) by approximately 4 mg/dL which would be associated with a 17% reduction in risk of coronary heart disease. It would also decrease the plasma concentration of fibrinogen by approximately 0.075 g/L, which would be associated with a 12.5% reduction in risk of coronary heart disease [146]. This translated into an overall 24.7% reduction in the risk of coronary heart disease from the consumption of 30 g of alcohol per day. Klatsky and Udaltsova (2007) further translated this into a 10% reduction in risk of all-cause mortality [42].

3.10. Lipid effects

A more recent meta-analysis of 44 experimental studies on 21 biomarkers for CVD calculated that there was a significant dose-response relationship between alcohol consumption and the plasma concentration of HDL, and its primary constituent apolipoprotein A1, which was not significant for the other lipid biomarkers [147]. This was a similar observation to that made by Rimm et al. [148] and Djoussé et al. [149], where HDL was the largest contributor to CVD risk reduction at 28.7%. HDL transports cholesterol from lipid-laden macrophages of atherosclerotic arteries to the liver for secretion into the bile, a process which is referred to as reverse cholesterol transport. Correspondingly, a dose-response relationship has been observed between alcohol consumption and reverse cholesterol consumption where alcohol stimulates the cellular cholesterol efflux and its esterification in plasma which is then incorporated into HDL particles [323]. HDL is also involved in inhibiting oxidation, inflammation, activation of the endothelium, coagulation, and platelet aggregation associated with atherosclerosis leading to coronary heart disease and peripheral artery disease [150]. In addition, HDL inhibits certain changes associated with the oxidative modification of LDL by endothelial and smooth muscle cells [151–153]. An increase in paraoxonase activity also follows an increase in the plasma concentration of HDL which may further protect LDL against oxidation [322]. Therefore, a low plasma concentration of HDL and its constituents is a risk factor for CVD. Studies comparing the effects of beer, wine and spirit consumption on the plasma concentration of lipids observed that they all increased the plasma concentration of HDL [154–156], suggesting that this an alcohol associated cardioprotective biological mechanism. Alcohol appears to increase the plasma concentration of HDL by stimulating the hepatic synthesis and secretion of its subcomponents, apolipoproteins A-I and A-II [157, 158].

3.11. Haemostasis effects

Normal haemostasis involves a delicate balance between coagulation and fibrinolysis, that is, lysis of the insoluble fibrin-platelet clot, which is regulated through the synthesis of fibrinolytic proteins. From in vitro and in vivo studies, alcohol has been observed to have two inter-related anti-thrombotic mechanisms involved in decreasing coagulation and increasing
Table 2
Summary of proposed effects of the alcohol component of all alcoholic beverages on biomarkers associated with CVD

<table>
<thead>
<tr>
<th>Specific effect</th>
<th>Proposed actions</th>
<th>Evidence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improves blood lipid profile (plasma concentration of “good” HDL to “bad” LDL) associated with atherosclerosis</td>
<td>Increases HDL cholesterol</td>
<td>Removes LDL cholesterol from blood vessel wall Prevents LDL oxidation and adhering to blood vessels walls to form atherosclerotic plaques</td>
</tr>
<tr>
<td>Decreases blood clotting (thrombosis) and improves blood flow</td>
<td>Decreases fibrinogen (blood clotter protein)</td>
<td>Reduces blood clotting by preventing stabilization of a forming blood clot</td>
</tr>
<tr>
<td></td>
<td>Decreases platelet activation</td>
<td>Reduces blood clotting by preventing initial aggregation and adhesion of platelets to form a blood clot</td>
</tr>
<tr>
<td></td>
<td>Decreases activity of haemostatic factors VII and VIII</td>
<td>Reduces blood clotting</td>
</tr>
<tr>
<td></td>
<td>Increases tissue type plasminogen activator (t-PA)</td>
<td>Increases fibrinolysis (dissolving of blood clots)</td>
</tr>
<tr>
<td></td>
<td>Increases urokinase type plasminogen activator (u-PA)</td>
<td>Increases fibrinolysis (dissolving of blood clots)</td>
</tr>
<tr>
<td></td>
<td>Decreases plasminogen activator inhibitor-1 (PAI-1)</td>
<td>Increases fibrinolysis (dissolving of blood clots)</td>
</tr>
<tr>
<td>Decreases local inflammation associated with atherosclerosis</td>
<td>Decreases C-reactive protein</td>
<td>Decreases atherosclerosis</td>
</tr>
<tr>
<td></td>
<td>Decreases pro-inflammatory cytokines</td>
<td>Increases concentration of adiponectin</td>
</tr>
<tr>
<td></td>
<td>Decreases soluble inflammatory mediators and adhesion molecules</td>
<td>Decreases concentration of adiponectin</td>
</tr>
<tr>
<td>Increases hormone levels associated with atherosclerosis</td>
<td>Increases concentration of insulin (and insulin resistance)</td>
<td>Reduces concentration of insulin (and insulin resistance)</td>
</tr>
<tr>
<td></td>
<td>Increases concentration of estrogen</td>
<td>Decreases atherosclerosis by effects on hepatic cholesterol metabolism to decrease plasma LDL concentrations</td>
</tr>
</tbody>
</table>

*Opinion of the author.
Specifically, alcohol decreases the concentration of plasma fibrinogen, decreases platelet aggregation and adhesiveness, and decreases the activity of factor VII and factor VIII associated with coagulation; and changes the concentration of the fibrinolytic proteins, tissue type plasminogen activator (t-PA), urokinase type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) [159–161]. Although Brien et al. [147] calculated the association between alcohol consumption and the plasma concentration of fibrinogen, which is converted into the fibrin-platelet clot, was calculated to be significant, the association with other haemostasis biomarkers was not significant as insufficient data did not enable meta-analysis. When the contribution of biological mechanisms to CVD risk reduction was calculated by Djoussé et al. [149] combined anti-thrombotic mechanisms contributed 5% to a reduced risk.

3.12. Inflammatory effects

There is increasing evidence that atherosclerosis is actually an inflammatory disease involving numerous cell types, such as macrophages, T-lymphocytes, platelets and endothelial cells, which produce and secrete numerous pro-inflammatory cytokines and growth factors that act locally to promote atherosclerosis [3, 162–164]. Accordingly, alcohol induces anti-inflammatory effects or responses associated with atherosclerosis. The association between alcohol consumption and inflammatory biomarkers was not calculated to be significant by Brien et al. [147]. Small randomised controlled clinical studies, however, as well as an observational study of 483 subjects followed for four years, suggest that moderate alcohol consumption reduces C-reactive protein, and the pro-inflammatory cytokines interleukin-6 and tissue necrosis factor-α [158, 165, 166]. Supporting the results of initial in vitro studies [167], a down-regulation and hence reduction in the plasma concentration of the soluble inflammatory mediators CD40 ligand, IL-16, monocyte chemotactic protein (MCP)-1, vascular cell adhesion molecule (VCAM)-1 and E-selectin has also been recently observed in high-CVD-risk subjects following 30 g of alcohol/day [168].

3.13. Hormonal effects

While Brien et al. [147] observed no association between alcohol consumption and inflammatory biomarkers, they did, however, calculate that there was a significant association with adiponectin. Adiponectin is an adipocyte hormone related to a reduced risk of coronary heart disease and diabetes. Insufficient data did not enable further meta-analysis for other hormonal biomarkers including insulin, or for endothelial biomarkers [147].

3.14. Optimal amount of alcohol

From Table 3, the optimal or most cardioprotective amount of alcohol was up to 15 g alcohol/day for women and up to 30 g alcohol/day for men, which is consistent with that determined by Rimm et al. [145]. These calculations suggest that alcohol reduces the risk of CVD by reverse cholesterol transport, haemostasis and insulin sensitivity mechanisms. In a clinical context, the alcohol-induced changes in HDL, fibrinogen and adiponectin are pharmacologically relevant and comparable if not greater than that induced by traditional US Food and Drug Administration-approved drug therapy [147].

In contrast to moderate alcohol consumption [169], heavy alcohol consumption is an established risk factor for hypertension and the development and progression of atherosclerosis, and is associated with lower fibrinolytic activity, pro-coagulation events, and higher blood viscosity. Alcohol-induced oxidative stress (production of reaction oxygen species), accumulation of fatty acid ethyl esters, modification of lipoproteins, and increased expression of pro-inflammatory cytokines and vascular cellular adhesion molecules, all contribute to and promote the formation of atherosclerotic plaques [170]. In addition, the alcohol-induced increase in blood pressure may counteract direct atheroprotective mechanisms. Recently, in vitro models of atherosclerosis, have shown that the primary breakdown product of alcohol, acetaldehyde, may also affect pro-inflammatory cytokines and vascular cellular adhesion molecules [171].

In summary, there is extensive evidence for plausible biological mechanisms for protection against coronary heart disease by low to moderate alcohol consumption which adds credence to a causal relationship. These mechanisms include the effects of alcohol via improved lipid factors, improved haemostatic factors, improved endothelial function, and a lower risk of diabetes mellitus [172, 173]. As concluded by Brien et al. [147], it was stated that: “Favourable changes in several cardiovascular...
### Table 3
Characteristics of 3 meta-analyses undertaken from 1999 to 2011 on the association between wine consumption and CVDs

<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of studies analysed</th>
<th>Total number of subjects</th>
<th>Time point of studies</th>
<th>Reduction in relative risk shown for moderate wine consumption</th>
<th>% Reduction in relative risk shown for moderate wine consumption (95% CI)</th>
<th>Optimal (lowest) amount of wine</th>
<th>Differentiation between alcoholic beverages observed between beer, wine and spirits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleophas (1999)</td>
<td>12 cohort and 2 case-control</td>
<td>209,418</td>
<td>1980–1995</td>
<td>Yes for MI</td>
<td>MI∼55%</td>
<td>10–40 g/day</td>
<td>Yes</td>
</tr>
<tr>
<td>Wine, beer and spirits and the risk of myocardial infarction: a systematic review. Biomed. Pharmacother. 53: 417-23.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MI risk is less for wine than for beer or spirits</td>
</tr>
<tr>
<td>Di Castelnuovo et al. (2002) Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105: 2836-44.</td>
<td>13</td>
<td>176,042</td>
<td>Yes for CVD</td>
<td>CVD = 0.68 (0.59–0.77)</td>
<td>150 mL/day</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CVD risk is less for wine than for beer (~0.78%)</td>
</tr>
<tr>
<td>Costanzo et al. (2011)</td>
<td>16 cohort and 5 case-control</td>
<td>293,917</td>
<td>1977–2009</td>
<td>Yes for CVD</td>
<td>CVD = 31% (19–24%)</td>
<td>21 g/day</td>
<td>Yes</td>
</tr>
<tr>
<td>Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis. European Journal of Epidemiology 26: 833-50.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CVD risk was similar for wine and for beer but there was no reduced risk for spirits</td>
</tr>
</tbody>
</table>

Biomarkers (higher levels of high density lipoprotein cholesterol and adiponectin, and lower concentration of fibrinogen) provide indirect pathophysiological support for a protective effect of moderate alcohol use on coronary heart disease.”

### 4. Reduction of CVD risk related to wine consumption – Is wine different to other alcoholic beverages?

Wine is an alcoholic beverage. The most abundant alcohol in wine is ethyl alcohol or ethanol, where the concentration of ethanol in ‘table’ wine generally ranges between 8 and 15% v/v (Day et al. 2002).

Of the available published literature identified in the undertaken review, the majority does not differentiate between wine, beer and spirits. St Leger et al. [22] published the first ecological1 analysis showing a strong inverse association between average per capita consumption of wine and mortality from coronary heart disease. An inverse association was observed for wine in both men and women, which was less strong for spirits and non-existent for beer. Renaud and de Lorgeril [144] in their assessment of the MONICA project2 attributed the French reduction in risk of coronary heart disease to their regular moderate consumption of wine and via haemostatic mechanisms. Their subsequent study of 36,360 French men observed that while both moderate wine and beer consumption was associated with a reduced risk of CVD, the association was greater for wine than for beer. Grønbaek et al. [175] in the Copenhagen City Heart Study also observed that the association with CVD and cerebrovascular disease was greater for wine than for beer, and was non-existent for spirits.

Prospective population studies, however, have provided no consensus that wine is more protective than beer or spirits against CVD. For example, Muk-

---

1 Ecological analyses examine relationships between exposure and outcome with population-level rather than individual-level data.

mal et al. [176, 177] found that all beverages were equally protective against MI but that only wine was protective against ischemic stroke in the US Health Professionals Follow-up Study. The first systematic review of ecological, case-control, and cohort studies in which specific associations were available for beer, wine and spirits consumption and risk of coronary heart disease was undertaken in 1996. It concluded that all the alcoholic beverages were cardioprotective [148]. Cardioprotection was also most associated with the common alcohol component.

4.1. Meta-analyses

Through a systematic search of the electronic database PUBMED from January 1980 up to May 2014, only three published papers of meta-analyses on the relationship between wine, beer and spirits and risk of CVD were identified (see Table 3).

From the analysis of 12 cohort studies from 1980 to 1995, including that of Grønbaek et al. [175], encompassing 284,416 subjects, Cleophas [178] calculated that consumption of one to four drinks/day of beer, wine or spirits was associated with a reduced risk of MI, although the level of significance was greatest for wine. Di Castelnuovo et al. [179] calculated from five cohort and eight case control studies involving 209,418 subjects, that the percentage reduction in risk from up to 150 mL wine/day was 32%. A similar but smaller association was seen with beer from 15 studies involving 208,036 subjects.

The most recent meta-analysis by Constanzo et al. [75] of 16 studies involving 306,370 subjects, calculated that the percentage reduction in risk of CVD for wine was 31%, where the optimal amount associated with this reduction was 21 g alcohol/day. A similar association was seen with beer from 13 studies but no association was seen for spirits.

One cohort study not considered in any of these three meta-analyses, however, was that conducted by Klatsky et al. [180], in which 128,934 Northern California adults were followed for approximately 20 years. Lifetime abstainers were the reference group. Frequency of wine consumption was associated with a lower risk for mortality, primarily related to a reduced risk of coronary heart disease than beer and spirit consumption. Similar risk reductions were associated with red, white and other types of wine. The observed percentage reduction in risk for coronary heart disease was 6% for consuming wine less than once per week, 14% for two to three days per week, 23% for four to five days per week and 33% for approximately daily wine consumption. The reduced risk of death for wine consumers was irrespective of age, cigarette smoking and education. Furthermore, one to two drinks/day of wine was observed to reduce the risk of CHD mortality by 60% whereas beer consumption only reduced the risk by 30% and spirit consumption did not reduce the risk at all. Klatsky et al. [180] concluded that since consumption pattern probably has a role in health effects, the usual pattern of ingesting wine slowly with food may be important [148, 181–183]. Such a pattern would attenuate a detrimental high blood alcohol concentration and prolong any beneficial effects on cells, organs and tissues.

Although evidence that protective mechanisms are related to the common alcohol component does not support the hypothesis that wine is most cardioprotective, the consistency and strength of the Klatsky et al. [180] data showing an apparent additional benefit from wine, raises the likelihood of a causal association caused by other components. Components of wine that might confer an additional cardioprotection are phenolic compounds. A comparison of potential effects of beer, wine and spirits on different biomarkers for CVD is shown in Table 4.

4.2. Role of phenolic compounds in CVD risk

In addition to alcohols, wine also typically contains a high concentration of phenolic compounds and their polymeric forms compared to other alcoholic beverages. Wine-derived phenolic compounds include the non-flavonoid classes of compounds such as the hydroxycinnamates, hydroxybenzoates and the stilbenes; and the flavonoid classes of compounds such as flavan-3-ols, flavonols and anthocyanins. While polymeric condensed tannins and pigmented tannins constitute the majority of red wine phenolic compounds, their large size precludes absorption and they are thus unlikely to directly contribute to any beneficial biological mechanisms for human health [184]. The total amount of phenolic compounds in a 100 mL glass of red wine is approximately 200 mg versus 40 mg in a glass of white wine [184–187].

While both wine and beer contain phenolic compounds, the concentration in wine is much greater than that in beer [188]. The types of phenolic compounds found in beer are also different, with different biological activities, to those found in wine. The wine-derived phenolic compounds, that are also present in the fruit and vegetable components of a
Comparison of effects of beer, wine and spirits on different CVD biomarkers/factors (adapted from Chivas-Blanch et al. 2013) [147]

<table>
<thead>
<tr>
<th>Alcoholic beverage</th>
<th>Wine</th>
<th>Beer</th>
<th>Spirits</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endpoints</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVD mortality</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MI</td>
<td>++</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td><strong>Risk factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-hypertensive effect</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Lipid profile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Apolipoprotein-AI, AII</td>
<td>++</td>
<td>±±</td>
<td>±±</td>
</tr>
<tr>
<td>Paraoxonase</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>LDL-cholesterol</td>
<td>±±</td>
<td>±±</td>
<td>±±</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>±±</td>
<td>±±</td>
<td>±±</td>
</tr>
<tr>
<td>Lipoprotein(a)</td>
<td>+</td>
<td>±±</td>
<td>±±</td>
</tr>
<tr>
<td><strong>Haemostasis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet aggregation</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Coagulation</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><strong>Endothelial function</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitric oxide</td>
<td>++</td>
<td>±±</td>
<td>±±</td>
</tr>
<tr>
<td>FMD dilation</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Insulin sensitivity</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Mechanisms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxidative stress</td>
<td>++</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td>Inflammation</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

++, ++: higher protective effect; +: protective effect; −: negative effect and ±: not clear or no effect.

Mediterranean-style diet, have also been associated with a reduced risk of CVD [189–192] In the PREVencion con Dieta Mediterranea (PREDIMED) study, the class observed to be strongest associated with a reduced risk of CVD is the flavanol class which includes catechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate and proanthocyanidins [191]. A primary source (32%) of flavanols in the daily diet is wine.

4.3. Mediterranean diet and lifestyle

Diet is also a significant source of variation in CVD risk and is accordingly a risk factor that can be readily modified to reduce CVD risk, as well as the impact of other important cardiovascular risk factors [193–197]. A systematic review of the evidence supporting a causal association between dietary factors and CHD ranked a traditional Mediterranean diet as the most likely dietary model to provide protection against CHD [198]. From a 30-year follow-up study in seven countries, the risk of CVD was at least two- to three-fold lower in countries consuming a Mediterranean-style diet compared to that in northern Europe and USA where the diet was generally higher in fat [199]. The core components of a Mediterranean-style diet include the high consumption of cereals, fruits, legumes, vegetables and wine, which typically contain a high concentration of phenolic compounds, have previously been associated with a reduced risk of cardiovascular disease [189, 191, 200–205]. For example, subjects placed on a Mediterranean-style diet for 46 months had a 50–70% lower risk of recurrent cardiovascular disease, compared to control subjects on a higher fat diet [201]. Furthermore, 55% of patients with metabolic syndrome (high blood pressure, a high cholesterol concentration and a high body mass index) who followed a Mediterranean-style diet for two years were symptom-less and had a reduced risk of cardiovascular disease at follow-up compared with only 14% of patients in the control group [4]. Introducing a Mediterranean-style diet into a non-Mediterranean US population group that included moderate wine consumption with meals was also associated with a reduced CVD risk in the population group after five years [206].

Relatively recent studies have indicated that consumers of wine have a reduced risk of CVD and all cause mortality, similar but additive to that for consumers of a traditional Mediterranean diet [55, 83, 207–209]. This is exemplified in an epidemiological study assessing the geographical distribution of cardiovascular disease in Spain, one of the 18 Mediterranean countries. A higher rate of cardiovascular disease was observed in those Spanish regions with the lowest per capita wine consumption, despite having, overall, a Mediterranean-style diet. The rate of CVD was, however, still less than that of countries consuming a higher fat and lower phenolic compound diet [210]. In addition, results of recent cohort studies have confirmed that, among patients with established coronary heart disease or at high-risk of this disease, moderate wine consumption is associated with lower incidence of cardiovascular events and total mortality as compared with abstainers [95, 138, 211, 212].

4.4. Confounding factors

Klatsky et al. (2003) mused whether the reduced risk of CVD of wine compared with beer and spirit consumption was partially related to the drinking pattern and associated traits of the consumers [180]. Wine consumers were considered to generally have
‘healthier’ traits, such as a healthier diet and lifestyle, and healthier amount and pattern of consumption [213–217].

An additional effect of adding red wine to a Mediterranean-style diet on the concentration of plasma lipids has been recently demonstrated. The inclusion of 10 to 20 g alcohol/day as wine was observed to reduce the ratio of low density lipoprotein to high density lipoprotein by 13%, independent of, and compared to regular physical exercise and/or a healthy Mediterranean-style diet [218]. If there is an excess of low density lipoprotein to high density lipoprotein, risk of atherosclerosis increases. This was also observed in addition to traditional statin drug therapy.

The US Alternative Healthy Eating Index 2010 (AHEI2010), a Mediterranean-style diet was comprised of 11 core components, including alcohol consumption of approximately 10 g/day. When alcoholic beverages such as wine were excluded from the diet, the cardioprotective effect of the diet was reduced by 10%, from 29% to 19% [219]. This observation supports that moderate wine consumption is an important synergistic as well as independent contributor to the cardioprotective diet. While statin drug therapy similarly reduces the risk of CVD by approximately 30%, it is also associated with adverse effects and is expensive [220].

Furthermore, while both wine and spirit consumption with food have been associated with a reduced risk of CVD compared with lifetime abstinence, only an inverse association between wine and CVD mortality has also been observed independent of consumption pattern [221].

4.5. Mechanisms of phenolic compounds in reducing CVD risk

Similar to the alcohol component of wine, wine-derived phenolic compounds exert multiple effects on the cardiovascular system. These include effects on plasma lipids, haemostatic effects on blood pressure and blood flow, anti-inflammatory effects and effects to enhance endothelial function; the latter is specific to phenolic compounds. As wine contains both alcohol and phenolic compounds, studies have often compared the effects of red wine and de-alcoholised red wine and an alcoholic beverage with not containing phenolic compounds on biological markers for CVD. The results of human clinical studies have been supplemented by in vitro, ex vivo and animal studies.

4.6. Effects on lipids

In contrast to the alcohol content of wine, wine-derived phenolic compounds do not affect the plasma concentration of HDL. A high plasma concentration of oxidatively modified low density lipoprotein (LDL) is also a risk factor for CVD, where oxidized-LDL initiates and aids all stages of the atherosclerotic process [153, 222]. The cholesterol that accumulates in atherosclerotic lesions originates primarily from LDL. Oxidized-LDL can also stimulate platelet activation associated with coagulation, and the activated platelets in turn can increase the susceptibility of LDL to oxidation [223].

Initial in vitro studies suggested that wine-derived phenolic compounds had predominantly lipid lowering effects, increasing the anti-oxidant capacity of plasma thereby protecting LDL against oxidation by circulating free radicals [187, 224–226]. Like other plasma anti-oxidants, the wine-derived phenolic compounds actually bind to the LDL particle by forming a glycoside bond, which protects it from oxidation [227]. The results of in vitro studies have not necessarily been supported by subsequent in vivo and ex vivo studies [226, 228–234]. The meta-analysis undertaken by Brien et al. (2011) consequently observed no change in the plasma concentration of low density lipoprotein after consumption of any alcoholic beverage [147]. However, in context with in vitro studies that have demonstrated that the wine-derived phenolic compounds are anti-oxidative in plasma, it is also possible that as alcohol itself is a pro-oxidant, the potentially anti-oxidative wine-derived phenolic compounds may merely counter the pro-oxidative alcohol concomitantly absorbed [234–236].

The plasma concentration of lipoprotein (a), another, although independent, lipid risk factor for atherosclerosis and CVD, however, may be reduced by wine-derived phenolic compounds. Estruch et al. (2011) and Chiva-Blanch et al. (2013) both observed a decrease in the concentration of lipoprotein (a) after 30 g alcohol/day as red wine for four weeks in healthy individuals and those at increased risk of CVD [174, 234].

4.7. Haemostasis

Similar to the alcohol component of wine, wine-derived phenolic compounds can modulate haemostasis [2]. There is in vitro evidence that
wine-derived phenolic compounds independently and additively reduce platelet aggregation [237–240], but the different flavonoid classes may exhibit different effects, particularly on arachidonic acid metabolism [241]. Specifically, wine-derived phenolic compounds have been observed to down-regulate cellular adhesion processes, which are responsible for the recruitment and activation of platelets and their aggregation at the site of vascular damage, hence reducing platelet aggregation [242].

Although it is difficult to distinguish between the effects of the alcohol and those of the phenolic components of wine in an in vivo study, several animal studies have demonstrated a difference between alcohol and wine-derived phenolic compounds on platelet aggregation [243–247]. Red wine and dealcoholised red wine, for example, consistently inhibited platelet aggregation at a significantly lower blood alcohol concentration than did an alcohol solution. Platelet aggregability has been observed to be dependent on the amount and pattern of alcohol consumption, such that binge patterns and heavy consumption have been observed to be associated with platelet rebound effects or hyperaggregability, which are implicated in sudden deaths after episodes of excessively heavy consumption and in alcoholics [248]. The type of beverage consumed may also affect platelet aggregability. For example, in contrast to spirits, irrespective of amount consumed, wine does not appear to be associated with platelet rebound effects [249]. This suppression of hyperaggregatability has been attributed to the inhibition of alcohol-induced lipid peroxidation by wine-derived phenolic compounds [238, 248, 250].

The consumption of both red and white wine has also been observed to increase fibrinolytic activity [251, 252], and wine-derived phenolic compounds have been observed to increase fibrinolytic activity independent of alcohol. For example, phenolic compounds such as catechin, epicatechin, quercetin, and resveratrol have also been observed to upregulate both t-PA and u-PA gene transcription, which results in the sustained increased expression of surface-localized fibrinolytic activity in cultured human umbilical vein endothelial cells [253].

4.8. Endothelial function

Another purported biological mechanism of wine-derived phenolic compounds is restoration of endothelial function. Dysfunctional endothelium is an early marker of atherosclerosis and actively contributes to the development of atherosclerotic plaques by, for example, inducing the proliferation of monocyte-derived macrophages that ingest oxidized-LDL to form foam cells, and also contributes to the development of blood clots [254]. Endothelial dysfunction may be induced by a high plasma concentration of lipid peroxides and oxidised lipids [255]. The synthesis of nitric oxide (NO) within endothelial cells plays a pivotal role in modulating homeostasis and preventing the initiation and progression of atherosclerosis [256]. One of the main effects of NO is vasodilation by reducing the contractility of vascular smooth muscle cells in the media layer of the vessel wall. Impaired NO synthesis is a feature of both atherosclerosis and endothelial dysfunction.

Supplementation of a high-fat diet with red wine has been observed to reverse or prevent endothelial dysfunction in several parallel-design studies [257, 258]. Several, but not all, cross-over design studies also observed that red wine or dealcoholised red wine improved endothelial function [259–266] and blood flow [267]. Red grape juice, red wine and dealcoholised red wine have all been observed in animal studies [268, 269], in vitro [270] and in vivo [271] to relax vascular endothelial smooth muscle. The synthesis and release of NO from endothelial cells is induced by inducing or up-regulating NO synthase gene expression (eNOS) [269, 272]. This effect appears independent of the ability of grape- and wine-derived phenolic compounds to protect against lipid oxidation.

In addition, the induced synthesis of NO by wine-derived phenolic compounds has other protective effects on both the early and late phases of the formation of the formation of atherosclerotic lipid plaques in the blood vessel wall (atherogenesis). For example, NO also inhibits platelet aggregation and platelet adhesion to the endothelium or lining of the blood vessel wall, preventing the formation of blood clots [273]. NO also controls the expression of genes involved in atherogenesis, such as the chemoattractant protein MCP-1, surface adhesion molecules CD11/CD18, P-selectin, vascular molecule-1 and intercellular adhesion molecule-1, thereby preventing leukocyte adhesion to the vascular endothelium and leukocyte migration into the blood vessel wall [274–276].

Endothelium dysfunction is also prevented by endothelin-1 (ET-1) antagonists; ET-1 is a potent vasoconstrictor peptide and its overproduction is another risk factor for atherosclerosis [277]. Wine-
derived phenolic compounds such as resveratrol have been observed *in vitro* to inhibit the synthesis of ET-1 by suppressing transcription of the prepro-ET-1 gene and by changing the morphology of the endothelial cell to modify tyrosine-kinase signalling and hence tyrosine phosphorylation [277, 278]. Inhibition is, however, dose-dependent.

4.9. Anti-inflammatory effects

In addition to the anti-oxidant effects of moderate wine consumption which affect atherosclerosis, there are specific inflammatory biomarkers of cell adhesion which are also modulated by wine-derived phenolic compounds. Cell adhesion molecules and cytokines participate in the recruitment of circulating leukocytes to the vascular endothelium and sub-endothelial spaces involved in initiating atherosclerosis. Plasma concentrations of vascular cell adhesion molecule -1 (VCAM-1) and intercellular CAM-1 (ICAM-1) have been observed to be significantly decreased by wine-derived phenolic compounds in some initial human *in vivo* studies [168, 279]. These may be indirectly modulated via effects on NO. Wine-derived phenolic compounds have also been observed to decrease the plasma concentration of C-reactive protein [279, 280], as have the inflammatory biomarkers, interleukin-1α (IL-1α), very late antigen-4 (VLA-4) lymphocyte expression and lymphocyte function associated antigen-1 (LFA-1) and macrophage-1 antigen (mac-1). These effects may be dose-dependent.

4.10. Other effects

In addition to the lipid, haemostatic, endothelium and anti-inflammatory effects, wine-derived phenolic compounds may also exhibit a cardioprotective effect by inhibiting the induced growth of vascular smooth muscle cells (VSMC) by angiotensin II. Angiotensin II is the main peptide hormone in the renin-angiotensin system. In addition to regulating blood pressure and circulating volume [281], angiotensin II also induces the growth of VSMC by stimulating the G protein-coupled angiotensin type 1 (AT1) receptor in VSMC, which activates multiple protein kinase pathway leading to VSMC protein synthesis. On vascular injury, the induced VSMC migrate, which may result in a ruptured atherosclerotic plaque and myocardial infarction. Thus an increased plasma concentration of angiotensin II is considered to contribute to the development of diseases characterised by VSMC growth, such as hypertension and atherosclerosis after vascular injury [282].

*In vitro*, several phenolic compounds appear to inhibit or suppress the angiotensin II-induced growth of VSMC. For example, both quercetin and resveratrol have independently been observed to interfere with the multiple protein kinase pathways and VSMC protein synthesis activated by angiotensin II [283]. In addition, both phenolic compounds have been observed to inhibit the angiotensin-converting enzyme (ACE), which converts angiotensin I to angiotensin II, and thus they may also decrease the plasma concentration of angiotensin II [284] and thereby inhibit the VSMC hypertrophy.

4.11. Specific compounds

Considering all the potential cardioprotective mechanisms postulated for wine-derived phenolic compounds, the effect of an alcoholic beverage on lipid oxidation and coagulation and fibrinolysis *in vivo* may depend on the balance between the pro-oxidant effects of the ethanol component and the concentration of phenolic antioxidant compounds in the beverage, as well as the diet of the consumer. It is also likely that the overall haemostatic effects purportedly associated with moderate wine consumption are attributable to the combined, additive, or perhaps synergistic effects of the ethanol component and the wine-derived phenolic compounds (Fig. 2). Although there are numerous classes of phenolic compounds, catechin, quercetin and resveratrol represent some of the candidates amongst the potentially bioactive phenolic compounds in wine [184].

To have any direct effects on lipids or on haemostasis, for example, the ingested wine-derived phenolic compounds and/or their active metabolites have to be absorbed into the blood stream, although not for direct effects on the small and large intestine. *In vivo* data have shown that small wine-derived phenolic compounds are absorbed into the blood stream in measurable quantity [224, 225, 229, 231, 257, 286, 295]. Catechin, quercetin, and resveratrol, administered either as single or multiple doses, have been subsequently shown to exert significant beneficial effects on established biological markers of CVD risk. These biological markers include endothelial function [272, 287–291] and blood pressure [292–295], as well as more broadly on haemostatic blood clotting and flow factors [296, 297] (Fig. 3). In addition, certain metabolites of catechin, quercetin
and resveratrol, have been shown to exert similar anti-oxidant, endothelial, anti-inflammatory and haemostatic effects *in vitro* to the parent phenolic compound [19, 299–301].

4.12. Does pattern of consumption matter?

Although the J-shaped relationship between alcohol consumption and CVD has been acknowledged in the World Health Organization’s *Global status report on alcohol* (2011), the report also recognises that as well as the amount consumed, the pattern of alcohol consumption also influences the potential health benefits of alcohol consumption [301]. The report includes the following statement: “The relationship between alcohol consumption and cardiovascular diseases is complex. Light to moderate drinking can have a beneficial impact on morbidity and mortality for ischaemic heart disease and ischaemic stroke. However, the beneficial cardioprotective effect of drinking disappears with heavy drinking occasions.”

Another relationship that is currently being considered by the WHO is that between different patterns of alcohol consumption and health consequences [302, 303]. Compared to studies examining amount of an alcoholic beverage and CVD risk, there have been relatively few prospective studies examining associations between CVD risk and frequency [175, 304–306].

Consequences such as CVD and specifically CHD, appear to be different depending on whether the same amount of alcohol is consumed in moderation and regularly over a week or on occasions of binge drinking, that is, on irregular heavy drinking occasions. A widely-accepted definition for binge drinking is five or more alcoholic drinks on one occasion, although studies differ in definition [307]. A meta-analysis of six observational studies compared the different drinking patterns. It demonstrated that the dose-response relationship between the amount of alcohol consumed and risk of CHD, for example, was significantly different between regular and irregular consumption [308]. The risk of CHD was increased with irregular consumption compared to abstinence. The irregular pattern appears to modify or negate the cardioprotective effects of alcohol consumption, and is also associated with biological mechanisms that increase the risk of sudden death and stroke [309, 310]. Conversely, regular consumption of any amount appeared cardioprotective. Wine consumption is least associated with irregular heavy patterns and most associated with regular moderate patterns [311, 312].

In the US Health Professionals Follow-up Study, among 38,077 men aged 40 to 75 years, consumption of an alcoholic beverage at least three to four days per week was inversely associated with the risk of MI. Consumption with meals did not substantially alter this association. Interestingly, men who increased
their consumption by a moderate amount during the 10 year follow-up had a decreased risk of myocardial infarction [176]. This observation is important given that past consumption habits appear strongly associated with CVD risk and current consumption is most strongly associated with lower risks of CVD and all-cause mortality compared with lifetime abstainers [313]. Similarly, in the UK Whitehall II Cohort Study of 10,308 men aged 35 to 55 years followed for 11 years, the optimal frequency of drinking to reduce the risk of CHD was observed to be between once or twice a week and daily, after adjustment for average volume consumed per week [305]. In a smaller Danish study of 25,052 men and 28,448 woman aged 50 to 65 years followed for approximately six years, the lowest risk of CHD in both men and women was observed with daily consumption of an alcoholic beverage compared with less than once per week [312]. All these findings are supported by a US prospective study of 20,765 current consumers followed for 14 years where the risk of CVD with approximate daily drinking was reduced by 81% (1–37%) [314] compared to the lowest frequency of 36 days/year.

5. Conclusions and extension of the CVD J-shaped relationship to all-cause mortality

In 2004/2005, CVD was the most costly disease and represented 11% of the total health expenditure in Australia. Of CVD expenditure, 40% was spent on coronary heart disease and stroke, where the majority of expenditure was for hospitalisations (more than 70% of their respective expenditure) followed by prescription pharmaceuticals (16% and 11%, respectively) and out-of-hospital services (10% and 8%, respectively). Deaths from CVD per se and particularly CHD and stroke increase with age [315]. As a proportion of the population, Australia’s population aged 65 years and over is projected to increase from 14% to between 18.3% and 19.4% in 2031. This increase will have significant implications for Australia in many spheres, including health [316].

The relationship between the consumption of alcoholic beverages and disease morbidity and mortality has been studied for at least five decades. It has been studied at the individual level and at the aggregate...
level, in case-control and in cohort prospective studies, in many countries, looking at both genders and across racial and other population groups.

From these studies, it can be concluded that the risk of CVD overall in the general population can be decreased by at least 25% with moderate consumption of alcoholic beverages and, in particular, moderate wine consumption. The reduction in CHD risk is major contributor to the overall CVD risk reduction, as it is the most common cardiovascular event.

From the small number of comparative studies, the reduction in risk may be greater for wine than for beer and spirits. The optimal pattern of moderate wine consumption to reduce risk is approximately daily, and the optimal amount is approximately 10 to 20 g alcohol/day. The meta-analysis by Klatsky and Udaltsova [42] suggests that the cardioprotection extends to approximately 40 g alcohol/day, as did studies by Doll et al. [317] and Mukamal [23, 50]. The cardioprotection afforded by alcoholic beverages decreases and the risk of any adverse effects increases, however, when consumption increases from light-to-moderate to heavy [40, 104, 114, 145, 318].

Extensive biochemical, pharmacological and physiological evidence supports the existence of a causal relationship between regular moderate wine consumption and cardioprotection. Cardioprotection by both the alcohol and phenolic compounds of wine, acting independently and synergistically, is potentially mediated by the following effects: lipid effects predominantly on HDL; haemostatic effects predominantly on plasma fibrinogen concentrations and platelet activation and adhesion; anti-inflammatory effects; effects on endothelial function; and other hormonal effects.

An aim of studies of the consumption of alcoholic beverages and mortality is to establish the net effects of alcohol at the population level and to derive conclusions at the aggregate level. The balance between net health benefits and risks from alcohol consumption is directly related to the distribution of causes of death in a population and to subgroups within a population. These subgroups include young adults, middle aged adults and the elderly. It has been observed for over two decades that the light to moderate consumption of alcoholic beverages such as wine also reduces the risk of death from all-causes within a population [37, 42, 49, 84, 89, 305, 319–321]. This J-shaped relationship between wine and all cause mortality results from the net sum of reduced risks of death from CVD, diabetes, cognitive function disorders such as dementia, as well as from certain cancers, and increased risks of death from short-term harms and long-term harms. Short-term harms include accidents such as drowning and suicides, and are generally associated with binge drinking patterns. Long-term harms include certain cancers, liver cirrhosis, pancreatitis and alcohol-related CVD, and are associated with continuous heavier consumption over many years, where risk increases linearly with consumption above moderation.

References


[44] Fillmore KM, Kerr WC, Stockwell T, Chikritzhs T, Bostrom A. Moderate alcohol use and reduced mortality risk:...


Renaud SC, Gueguen R, Conard P, Lanzmann-Petithory D, Orgogozo JM, Henry O. Moderate wine drinkers have lower...


[167] Sacanella E, Vázquez-Agell M, Mena MP, Antúnez E, Fernández-Solá J, Nicolás JM, Lamuela-Raventós RM, Ros E, Estruch R. Down-regulation of adhesion molecules and other inflammatory biomarkers after moderate wine con-


...


Demrow HS, Folts JD, Gastric or IV administration of French red wine but not white wine inhibitions in vivo platelet activity and thrombosis in stenosed canine coronary arteries. J Am Coll Cardiol. 1994;23:49A.


